Sort   by:  
 Page size 
TranscriptomicsTargeting the MTOR-AKT pathway in DLBCL
The mTOR (mammalian Target of Rapamycin) pathway is constitutively activated in Diffuse Large B-Cell Lymphoma (DLBCL). mTOR inhibition has been shown to have clinical activity in patients with DLBCL, although overall response rates remain low. We therefore evaluated differences in the transcriptome...
ORGANISM(S): Homo sapiens 
2012-04-29 | E-GEOD-27255 | biostudies-arrayexpress
TranscriptomicsHDACI and DAC induce specific epigenetic profile in DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoid neoplasm in the world representing 30-40% of all lymphomas. Standard immunochemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) ensures cure in 60 to 65% of patients, while the rest progress or r...
ORGANISM(S): Homo sapiens 
2011-02-15 | E-GEOD-27226 | biostudies-arrayexpress
Sort   by:  
 Page size